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Objective: Durability assessment of mitral valve repair for degenerative valve incom-
petence is limited to reoperation as a primary indicator and valve-related risk factors
for late death as a secondary indicator. We assessed serial echocardiographic follow-
up of valve function as an indicator of the durability of mitral valve repair.
Methods and Results: In 348 patients having undergone mitral valve repair for degen-
erative valve incompetence, clinical outcome was excellent: 10 years after repair, sur-
vival was 80.1% and freedom from reoperation 94.4%. However, freedom frommitral
regurgitation (.2/4), 98.7% at 1 month, decreased to 82.2% at 5 years and 64.9% at
10 years. The linearized recurrence rate of mitral regurgitation (.2/4) was 3.2% per
year. Recurrence rate was higher in patients with Barlow disease (6.0%) and lower in
those with fibroelastic deficiency (2.6%) (P 5 .01). Performing chordal shortening,
the nonuse of sliding plasty and the nonuse of an annuloplasty ring were determined
to be factors predicting recurrence of mitral regurgitation. In reconstructions avoiding
these risk factors, recurrence rate decreased to 2.4%. There was no difference between
Barlow disease and fibroelastic deficiency: 2.9% versus 2.2% (P . .05). Recurrent
regurgitation is characterized by leaflet prolapse, thickening, and calcification.
Conclusion: When optimal surgical techniques are used, the residual recurrence rate
of mitral valve regurgitation remains between 2% and 3% per year and is related to
progressive degeneration of the chordae and the leaflets. Long-term results of mitral
valve repair in Barlow disease are essentially the same as in fibroelastic deficiency.
I
n a recent report, we1 demonstrated that the linearized recurrence rate of recur-
rent mitral regurgitation greater than 2/4 after surgical repair was 3.7% per year
in patients with degenerative valve disease. Inadequate surgical techniques
could only partially explain this recurrence of regurgitation. In patients receiving
optimal repair techniques, the recurrence rate of regurgitation dropped to 2.5%
per year. We suggested that the progression of the degenerative disease of the valve
was responsible for this small but constant recurrence rate. Recurrence rates of re-
gurgitation were not previously reported because most studies so far were focusing
on survival and reoperation rates, which were found to be excellent.2-9 In our study,
survival was also high (80.1% at 10 years), as was freedom from reoperation (94%
at 10 years). Diseased valves can be successfully repaired by a variety of surgical
techniques, and our results confirmed this high immediate operative success:
98.3% of the patients was free of significant (.2/4) regurgitation 1 month postop-
eratively as defined by echocardiography.1 However, as recent studies have demon-
strated, myxomatous valve leaflets are structurally, biochemically, physically, and
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NYHA 5 New York Heart Association
SAM 5 systolic anterior motion
mechanically abnormal10 and a certain progression of the dis-
ease can be expected after repair. Therefore, we were not sur-
prised to find that 7 years postoperatively only 71% of the
patients were still free of greater than 2/4 regurgitation.1
This finding was confirmed by David and associates9 in
a more recent study. They found that 12 years postopera-
tively, only 73% of the patients were free from moderate or
severe mitral insufficiency of more than 3/4, a result is
even worse than that of our study.
In patients with degenerative mitral valve disease, Car-
pentier and colleagues11 distinguished two different forms:
Barlow disease and fibroelastic degeneration. These two
diseases may not have the same outcome, because Barlow
disease is a more generalized degeneration of the valve.
The goal of the present study was to analyze the recur-
rence of mitral regurgitation in terms of incidence and degree
in a series of patients undergoing mitral valve repair for de-
generative disease, with special reference to Barlow disease.
All patients were operated on in the same institution, by the
same surgeon, with standard repair techniques.
Materials and Methods
Patient Population
During the period from July 1989 through December 2005, 1596
mitral valve operations were performed by the same surgeon
(W.F.), 945 replacements and 651 repairs. Four hundred fifty-two
patients had degenerative mitral valve disease: 104 underwent
replacement and 348 (77%) repair. The repair rate increased from
43% in 1989 to 95% in 2005. The indications to prefer mitral valve
replacement above repair were as follows: Barlow disease (62%),
nonsinus rhythm (41%), anterior mitral leaflet involvement (30%),
severe calcification of the mitral annulus (20%), concomitant aortic
valve replacement (12%), and systolic anterior motion (SAM) (3%).
Mitral Valve Characteristics
On the basis of the preoperative echocardiogram and a detailed
drawing of the operative findings, valve pathologic status was iden-
tified and coded at the end of the operation. We differentiated
between Barlow disease and fibroelastic deficiency on the basis of
gross appearance of the valve, according to Carpentier,11 Fornes,12
and their associates. The following criteria were used to classify the
patients into these two groups:
 Barlow disease: myxoid appearance of the whole valve with
excess tissue and a dilated annulus.
 Fibroelastic deficiency: restriction of thickening to the
prolapsed area(s), the remaining valve tissue being more
transparent, not thickened, without excess tissue, and the
annulus being dilated or not.The Journal of ThoEighty-three patients were classified as having Barlow disease
(24%) and 265 (76%) as having fibroelastic deficiency. Demo-
graphic data and mitral valve characteristics are listed in Table 1.
Surgical Techniques
Overall in our institution, the average repair rate was 77%, and this
rate increased continuously from 43% in 1989 to 95% in 2005. The
repair rate for Barlow disease was 33% in 1989, 33% in 1995, 77%
in 2000, and 85% in 2005. For fibroelastic deficiency it was 50% in
1989, 88% in 1995, 88% in 2000, and 100% in 2005. For repair,
classic techniques described by Carpentier and others were used.
Prolapse of the posterior leaflet was preferentially corrected by qua-
drangular resection when the prolapsing segment was billowing and
in most cases combined with chordal rupture or elongation, to
remove this diseased part of the valve as much as possible. When
the remaining part of the posterior leaflet showed excess tissue (as
in Barlow disease), the resection was combined with a sliding leaflet
procedure including two triangular resections of the remnants of the
nonprolapsing posterior leaflet. When there was no excess tissue in
the remaining portion of the posterior leaflet (as in fibroelastic defi-
ciency), a sliding procedure was performed, but without removal of
tissue of the remaining posterior leaflet. The size of the annulus was
adjusted by mattress sutures passed through the annulus, which is
a procedure focused rather on an adequate reduction of the dilated
annulus and is altered from Carpentier’s described techniques.
This was done to obtain an evenly distributed reduction of the
TABLE 1. Demographic data and mitral valve characteris-
tics
Total Barlow FED
No. of patients (%) 348 83 (24%) 265 (76%)
Age, y (range) 63 (29–86) 61 (29–79) 64 (31–86)
Male sex 247 55 (62%) 192 (61%)
Cardiac rhythm
Sinus 268 (77%) 61 (73%) 207 (78%)
Atrial fibrillation 75 (21.5%) 22 (27%) 53 (20%)
Other 5 (1.5%) 0 (0%) 5 (2%)
Leaflet involvement
Anterior (%) 18 (5%) 2 (2%) 16 (6%)
Posterior (%) 220 (63%) 14 (17%) 206 (78%)
Bileaflet (%) 110 (32%) 67 (81%) 43 (16%)
Leaflet condition
Prolapse 321 (92%) 79 (94%) 242 (91%)
Calcifications 6 (1.7%) 0 (0%) 6 (2%)
Normal aspect 8 (2.3%) 0 (0%) 8 (3%)
Cleft formations 14 (4%) 5 (6%) 9 (3%)
Chordae
Rupture 241 (69%) 34 (41%) 207 (78%)
Elongations 57 (16%) 31 (37%) 26 (10%)
Thickening 5 (2%) 3 (4%) 2 (1%)
Normal aspect 45 (13%) 15 (18%) 30 (11%)
Annulus
Dilated, not calcified 320 (92%) 73 (88%) 247 (93%)
Dilated, calcified 24 (7%) 10 (12%) 14 (5%)
Not dilated 4 (1%) 0 (0%) 4 (2%)
FED, Fibroelastic deficiency.racic and Cardiovascular Surgery c Volume 135, Number 2 275
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of the posterior leaflet. When the annulus showed no or mild dilata-
tion, the prolapse was preferentially corrected by artificial chordae.
Prolapse of the anterior leaflet was never corrected by leaflet seg-
ment resection but by chordal transfer or artificial chorda implanta-
tion. Prolapse induced by chordal elongation was treated by chordal
shortening. This was done by either chordal burring or papillary
muscle repositioning. The latter procedure was mostly used for
anterior leaflet prolapse or commissural prolapse of both leaflets.
Mitral ring annuloplasty was performed in most cases to complete
the repair, except in extreme situations either when the annulus
was not or only slightly dilated or when the anterior leaflet was so
large that SAM could be expected after ring annuloplasty.
In every patient, the specific surgical repair techniques used were
identified and coded at the end of the operation: intervention at the
leaflet (none, quadrangular resection, triangular resection, plication,
cleft closure), intervention at the annulus (none, sliding plasty, pli-
cation, decalcification), at the chordae (none, shortening, transposi-
tion, artificial chordae), at the papillary muscles (none, shortening),
and the placement of an annuloplasty ring (yes or no). The frequency
with which these different techniques were used is listed in Table 2.
Follow-up
Clinical and echocardiographic follow-up were performed shortly
before hospital discharge, at 1 month, and then every 6 months by
the referring cardiologist. Survival, reoperation, cerebrovascular
TABLE 2. Surgical data in mitral valve repair
Total Barlow FED
MV repair
Segmental resection leaflet 274 59 (71%) 215 (81%)
Other leaflet intervention
(patch, plicature, cleft suture)
13 4 (5%) 9 (3%)
Chordal shortening 22 12 (15%) 10 (4%)
Chordal transfer 27 5 (6%) 22 (8%)
Chordal replacement
with PTFE sutures
48 38 (46%) 10 (15%)
Decalcification and reconstruction
of mitral annulus
8 3 (4%) 5 (2%)
Mitral annulus reduction
By sliding leaflet technique 243 48 (58%) 195 (74%)
By annulus plication 17 6 (7%) 11 (4%)
Mitral ring annuloplasty
None 11 4 (5%) 7 (3%)
Rigid Carpentier ring 326 79 (95%) 247 (93%)
Flexible ring 11 0 (0%) 11 (4%)
Ring size
Smaller than 34 32 (39%) 223 (84%)
34 or larger 51 (61%) 42 (16%)
Concomitant cardiac surgery
CABG 74 10 (12%) 64 (24%)
Aortic valve 9 0 (0%) 9 (3%)
Tricuspid valve 30 6 (7%) 24 (8%)
Redo surgery 2 0 (0%) 2 (1%)
FED, Fibroelastic deficiency;MV,mitral valve; PTFE, polytetrafluoroethylene;
CABG, coronary artery bypass grafting.276 The Journal of Thoracic and Cardiovascular Surgery c Febaccidents, bleeding complications, anticoagulation therapy, New
York Heart Association (NYHA) function class, and cardiac rhythm
were registered. On the echocardiogram, mitral regurgitation was
classified from grade 1 to 4.
Statistical Analysis
The Cox proportional hazards methods were used to analyze the
data on recurrence of mitral regurgitation in time. For survival and
follow-up of events, Kaplan–Meier techniques were used with
log–rank testing. For recurrence of mitral regurgitation, a classic
Kaplan–Meier technique was used with the first echocardiographic
follow-up date demonstrating the recurrence of regurgitation as date
of the event. Since the mitral regurgitation did in fact recur between
the last echocardiogram without regurgitation (or the date of the op-
eration if the echocardiogram before hospital discharge showed mi-
tral regurgitation) and the first echocardiogram with regurgitation,
an interval-censored survival curve using the Turnbull algorithm
Figure 1. A, Survival of the whole patient group. B, Freedom from
reoperation for the whole patient group and for the two subgroups
(fibroelastic deficiency and Barlow disease; P 5 .002).ruary 2008
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mum likelihood estimate on the basis of interval-censored data, the
mass was always placed at the at rightmost limit of the interval.
Results
Survival and Reoperation Rate
Hospital mortality was 1.6%. Survival at 5 years was 93.1%
6 1.5% and 80.1% 6 3.7% at 10 years (Figure 1, A). Sur-
vival was identical between patients having Barlow disease
and patients having fibroelastic deficiency (P . .05). Sur-
vival did not differ significantly between patients with or
without associated coronary artery bypass graft procedures
(P . .05). Freedom from reoperation at 5 years was 95.4%
6 1.4% and 94.4% 6 1.6% at 10 years for all patients (Fig-
ure 1, B). Freedom from reoperation for fibroelastic defi-
ciency was better (96.6% at 10 years) than for Barlow
disease (86.1% at 10 years) (P 5 .002).
Clinical Outcome and Morbidity
No patient was lost to clinical follow-up. At least one echo-
cardiographic examination was obtained in every patient.
In 19 patients, the only echocardiogram was the discharge
echocardiogram. The remaining patients received several fol-
low-up echocardiograms with a mean of 4.6 echocardio-
grams per patient, ranging from 2 to 16. In total, the
clinical follow-up represents 1836 patient-years, with
a mean follow-up of 5.9 6 3.4 years (range 0.5–15.3 years).
During the most recent postoperative follow-up period,
NYHA class was recorded. Corresponding to the mean fol-
low-up time of the entire population, 91.3% of the patients
improved by at least one NYHA functional class. Seventy-
five percent of the patients were in class I, 19% in class II,
5% in class III, and 1% in class IV. Postoperatively, 71%
of the patients had sinus rhythm, 22% had atrial fibrillation,
and 7% had a pacemaker. Anticoagulation therapy using cou-
marin was given during the follow-up period in 35% of the
patients. Freedom from thromboembolic events and/or major
anticoagulant-related bleeding was 93.5%6 1.5% at 5 years
and 86.7% 6 2.7% at 10 years for the whole group.
Immediate Surgical Result of Mitral Valve Repair
Operative success of the mitral valve repair was assessed by
the echocardiographic examination of mitral valve function
within the first 4 weeks postoperatively. At 1 month postop-
eratively, 98.7% of all patients had no or trivial mitral regur-
gitation (0/4 or 1/4). In patients having fibroelastic
degeneration, this was 99.8% and in Barlow disease 97.1%.
Suture dehiscence of the ring annuloplasty was encountered
in 2 patients. Endocarditis of the repaired valve did not occur
in this series.
Recurrence of Mitral Regurgitation
Postoperative echocardiography was performed serially at 6-
month intervals. According to the classic Kaplan–Meier ap-The Journal of Thorproach, freedom from failing repair (regurgitation . 2/4)
was 98.7% 6 1.2% at 1 month, 82.2% 6 3.7% at 5 years,
and 64.9% 6 5.6% at 10 years (Figure 2). When the inter-
val-censored Turnbull approach is used to calculate the free-
dom from recurrence of mitral incompetence, similar results
are obtained. Freedom from failing repair is better in fibro-
elastic deficiency and worse in Barlow disease (P 5 .01).
Remarkable is the constant rate of recurrence of mitral regur-
gitation after the first 6 months postoperatively. When the
classic Kaplan–Meier curves are restricted to the period
from 6 months until 7 years postoperatively, a linear regres-
sion can be made, allowing calculation of recurrence rates per
year. Recurrence of mitral regurgitation of greater than 2/4
occurs at a constant rate of 3.2% per year for the whole
patient group (Table 3). The linearized curves are shown
for the patients with fibroelastic disease and Barlow disease
separately in Figure 3, A and B.
Figure 2. Freedom from recurrent mitral regurgitation (MR) of
greater than 2/4 for the whole patient group and for the two sub-
groups (fibroelastic deficiency and Barlow disease; P 5 .01).
TABLE 3. Linearized recurrence rates (in percent per year)
for recurrent mitral regurgitation greater than 2/4
Linearized recurrence
rates for mitral
regurgitation > 2/4
All patients FED Barlow
Overall 3.2 2.6 6.0
Without surgical risk 2.4 2.2 2.9
With surgical risk 4.7 3.6 14.9
FED, Fibroelastic deficiency. When only patients without surgical risk fac-
tors are included, the rates for fibroelastic disease and Barlow disease
are similar.acic and Cardiovascular Surgery c Volume 135, Number 2 277
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Regurgitation After Repair
During the follow-up period, a subpopulation of 55 patients
was identified as showing recurrence of significant mitral
valve regurgitation (.2/4) and could be compared with the
remaining 293 patients who did not. Cox proportional hazard
analysis (Table 4) revealed that the subpopulation showing
recurrence of regurgitation was mainly characterized by
a higher incidence of Barlow disease (P 5 .01). Bileaflet
mitral valve degeneration as such showed a trend toward
higher recurrence of regurgitation (P 5 .06). The absence
of ruptured chordae (P 5 .01) as well as the presence of
elongated chordae (P 5 .003) predicts also recurrence of re-
Figure 3. Linearized recurrence curves for patients with fibroelas-
tic deficiency (A) and patients with Barlow disease (B). Separate
curves are shown for patients having surgical risk factors (nonuse
of annuloplasty ring, nonuse of sliding plasty, or performance of
chordal shortening) and for patients not having these factors.
The concomitant slopes of these curves are shown in Table 3.
MR, Mitral regurgitation.278 The Journal of Thoracic and Cardiovascular Surgery c Fegurgitation. Specific surgical repair techniques had a predic-
tive value for recurrence of regurgitation: the nonuse of
a sliding annuloplasty (P5 .002), the use of chordal shorten-
ing (P 5 .01), and the nonuse of an annuloplasty ring in
general (P 5 .001) predict inferior outcome.
We separated the study populations into subgroups. The
first bears the surgical risk factors as determined above (ie,
absence of a stiff annuloplasty ring and/or presence of
chordal shortening and/or no use of sliding annuloplasty)
and the second does not. We could define two significantly
different recurrence rates of mitral regurgitation (Table 3):
patients having the surgical risk factors had a recurrence
rate of regurgitation greater than 2/4 of 4.7% per year. How-
ever, patients not having these surgical risk factors still had
a recurrence rate of 2.4% per year.
When we divided the patient population into patients hav-
ing Barlow disease and patients having fibroelastic defi-
ciency, the risk factors became more focused (Table 4). In
fibroelastic deficiency, the nonuse of a quadrangular resec-
tion predicts recurrence of regurgitation (P 5 .02) as well
as the nonuse of an annuloplasty ring (P5 .04) and the non-
use of a sliding annuloplasty (P 5 .01). In Barlow disease,
the presence of abnormal or elongated chordae (P 5 .02) is
the main predictor of regurgitation, as well as the use of
chordal shortening (P 5 .04), the nonuse of polytetrafluoro-
ethylene chordae (P 5 .02), and the nonuse of an annulo-
plasty ring (P 5 .004). When the two populations bear the
corresponding risk factors, recurrence rates are 3.6% per
year for fibroelastic deficiency and 14.9% per year for Barlow
disease (P, .05) (Table 3, Figure 3, A and B). When the cor-
rection for the corresponding surgical risk factors is made for
these two patient populations (Table 3), the following linear-
ized recurrence rates are found: 2.9% per year for Barlow
TABLE 4. Factors predictive for mitral regurgitation greater
than 2/4
Cox analysis;
mitral regurgitation > 2/4
All patients FED Barlow
Barlow 0.01 — —
Bileaflet disease 0.06 0.6 0.7
Leaflet prolapse 0.04 0.05 0.9
Annulus dilatation 0.69 0.7 0.9
Annulus calcification 0.74 0.8 0.9
Chordae abnormal 0.75 0.9 0.02
Elongation (presence of) 0.003 0.8 0.02
Rupture (absence of) 0.01 0.1 0.4
Nonuse of quadrangular resection 0.06 0.02 0.6
Nonuse of sliding plasty 0.002 0.01 0.2
Nonuse of PTFE 0.6 0.2 0.02
Performing chordal shortening 0.01 0.9 0.04
No ring 0.001 0.04 0.004
FED, Fibroelastic deficiency; PTFE, polytetrafluoroethylene.bruary 2008
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difference between the two rates is not statistically significant
(P . .05).
Echographic Characteristics of Recurrent Mitral
Valve Regurgitation
The echocardiograms from the patients showing recurrence
of greater than 2/4 mitral regurgitation were analyzed in
an attempt to define possible mechanisms of valve incompe-
tence. We found that 42% of these patients had a leaflet pro-
lapse that was mostly an anterior leaflet prolapse (in 81% of
cases). In the group with fibroelastic deficiency, 41% of the
patients had a leaflet prolapse (80% anterior), and about the
same results were seen in the group with Barlow disease:
43% showed leaflet prolapse (83% anterior). Chordal rupture
or elongation was found in 24% of the patients. Leaflet thick-
ening was diagnosed in 50% of the patients (50%with fibroe-
lastic deficiency and 43% with Barlow disease), and leaflet
calcifications were detected in 25% of the patients (29% of
patients with fibroelastic deficiency and 7% of those with
Barlow disease). These calcifications were pre-existent in
only 4% of the patients. Left ventricular function was de-
scribed as reduced in 55% of the patients, and 59% had a non-
sinus rhythm.
Discussion
From the early days of mitral valve repair, Carpentier and as-
sociates11 made a clear distinction between Barlow disease
and fibroelastic deficiency. In later work, Fornes and col-
leagues12 investigated the histologic differences but were un-
able to obtain a clear distinction between the two entities on
this basis. They concluded ‘‘obviously the surgeons’ diagno-
sis based on clinical examination, echocardiographic findings
and operative macroscopical findings of the mitral valve
apparatus should remain the gold standard.’’ We followed
their macroscopic criteria to separate Barlow disease from
fibroelastic deficiency.
Our results are in concordance with the available clinical
reports showing good clinical outcome and low reoperation
rates after repair.2–9 We also found a low reoperation rate
at 10 years (94.4% freedom) and an excellent clinical out-
come. On the other hand, the present article confirms our pre-
vious findings that recurrence of mitral valve insufficiency
based on echocardiographic studies is more frequent than
the reoperation rate indicates.1 Obviously, reoperation rate
is not an optimal predictor of recurrent mitral valve regurgi-
tation and is not the best parameter to estimate durability of
valve repair. However, long-term results (over 20 years) after
repair for mitral valve prolapse were reported in 2001,13 and
they suggest that the durability of mitral valve repair will be
limited but that the therapeutic consequences remain delayed.
Reoperation rate after repair constantly increases: at 5 years it
is 7%, at 10 years 11%, at 15 years 16%, and at 19.5 years
20%. Survival at 19.5 years is 30%.The Journal of ThorAs mentioned earlier, our immediate postoperative echo-
cardiographic results were excellent: 98.7% of the patients
had no or trivial (0/4 or 1/4) mitral valve regurgitation. In fi-
broelastic deficiency this was 99.8% and in Barlow disease
97.1%. However, despite such highly successful repair, re-
currence of mitral valve incompetence occurs at a constant
rate during the following years. Causes of recurrence of
regurgitation after mitral valve repair may be classified as
procedure-related or valve-related.
Concerning procedure-related or surgical factors, our
study revealed nothing new: the nonuse of an annuloplasty
ring, nonuse of a sliding plasty, and the use of chordal short-
ening instead of transposition or artificial chordae were fac-
tors of recurrence of mitral valve incompetence, as already
shown by others.6 In a larger study, Gillinov and coworkers5
demonstrated that the instantaneous risk of reoperation con-
sists of two hazard phases: a peaking early hazard phase in
the first year after the operation followed by a slow-rising
late hazard phase of reoperation. They showed that patients
with an isolated anterior leaflet prolapse had an increased
early risk of reoperation. Also, chordal shortening increased
the risk of early repair failure and the use of ring annuloplasty
and leaflet resection decreased the risk of reoperation in the
late hazard phase. Nevertheless, most of these surgical factors
are indirectly related to the process of valve degeneration,
mainly in the chordae, which are severely structurally altered
by the degenerative process. Therefore, besides overall pro-
gression of the valve disease, specific repair techniques
may influence recurrence of regurgitation. For example, qua-
drangular resection of the billowing and degenerated portion
of a posterior leaflet may fully exclude the diseased part of the
valve and can be expected to be more durable than shortening
of elongated and severely affected chordae, which are short-
ened but left in place. Obviously, the degeneration of the
chordae progresses after repair, which is shown by the post-
operative echocardiographic studies. More than 40% of the
patients showing significant recurrence of regurgitation
have a new leaflet prolapse, mainly from the anterior leaflet.
This may originate either from progressive degeneration of
the valve or from retraction of the repaired posterior leaflet
segment, resulting in relative prolapse. The high incidence
of chordal rupture or elongation suggests the first mecha-
nism. Furthermore, half of these valves have leaflet thicken-
ing and one third have new calcifications. These findings
suggest that the chordae elongate and the leaflet degenerates
further. This explains also why implantation of artificial chor-
dae is associated with superior results.14 Maybe the use of
artificial chordae should be promoted and even used as a stan-
dard technique in every repair as a prevention of recurrence
of regurgitation. Regarding the risk for SAM, the use of large
annuloplasty rings (sizes 36 to 40) has recently been advo-
cated instead of avoiding the use of an annuloplasty ring.15
Myxomatous degeneration of the valve affects the leaflets
as well as the subvalvular apparatus, and the extent ofacic and Cardiovascular Surgery c Volume 135, Number 2 279
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Although histologic alterations in myxomatous valves have
been well described in the past,16-20 only recently have the
mechanical properties of myxomatous mitral valves been ex-
tensively studied,10 and it is shown that myxoid leaflets are
more extensible and less stiff than normal valves. It is also
demonstrated16 that cells of the chordae of myxomatous
valves produce more glycoaminoglycans, giving them their
characteristic thickening and gelatinous nature, which may
account for their mechanical weakness.21 All these patho-
physiologic findings may help to explain why a progressive
incidence of mitral valve incompetence is found after initial
adequate repair. When patients bearing the surgical risks
(ie, use of chordal shortening, nonuse of an annuloplasty
ring, and nonuse of sliding plasty) are excluded from the
analysis, recurrence rate drops from 3.2% per year to 2.4%
per year. This residual rate of 2.4% per year can be attributed
to the phenomenon of valve degeneration. However, two dis-
tinct forms of valve degeneration were described: fibroelastic
deficiency and Barlow disease.11,12 Because Barlow disease
is a more generalized form of valve degeneration, the pro-
gression of the degenerative process in these valves can be
expected to be more pronounced and reflected in the recur-
rence rates of mitral regurgitation. At first glance this is cor-
rect: the recurrence rate in Barlow disease is 6.0% per year
and in fibroelastic deficiency 2.6% per year. However, the
impact of the surgical risk factors is so high that after correc-
tion for these techniques, the residual recurrence rate de-
creases to almost that of fibroelastic deficiency (2.9 vs
2.2% per year).
It can be concluded that the long-term result of mitral
valve repair in Barlow disease is essentially the same as in
fibroelastic deficiency provided optimal surgical techniques
are used. A constant recurrence rate of regurgitation (2%–
3% per year) remains present owing to progression of the
degenerative process in the native valve.
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Discussion
Dr Aubrey C. Galloway (New York, NY). This was an excellent pa-
per. You should be congratulated on achieving echographic and
clinical follow-up over time so that we can draw some significant
conclusions. To review a couple of points: 348 patients, about
24%, had Barlow disease by gross pathologic determination. The
linearized rate of recurrence of mitral regurgitation was higher
clearly in the Barlow population, but you were able to identify cer-
tain other risk factors. Most prominently, you showed, similar to
what others have shown, that chordal shortening does not work
well in Barlow patients and that the absence of an annuloplasty de-
vice or use of a flexible annuloplasty device was associated with
a higher failure rate. In contrast, you showed improved late results
with chordal replacement and rigid devices. Therefore, if you used
those ‘‘optimal techniques,’’ the late recurrence rate dropped to an
acceptable but still significant 2.9% per year over time.ruary 2008
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technique and absence of the use of a rigid ring were predictors of
late recurrence, which you did not put in the presentation but did
put in your manuscript. You also observed that a billowing anterior
leaflet was predictive of late failure in fibroelastic deficiency, which
brings me to my first point. It seems that the gross characterization of
valve disease into Barlow versus fibroelastic deficiency is probably
not that useful or specific a way to fine tune our predictions as to who
is at risk for late failure. There is probably a spectrum of disease that
we have not figured out that is not apparent by gross visual inspec-
tion at the time of surgery. Maybe we need better phenotypic char-
acterizations or even genotypic ways to characterize these valves.
This brings me to the fundamental question: if we use optimal
surgical techniques but still have a built-in failure rate of somewhere
between 2.2% and 2.9%, can a valve phenotype be identified that
would have a high enough risk of failure that chordal replacement
should be done prophylactically since you showed that this tech-
nique improved outcomes?
Dr Flameng. Yes, we clearly do not have any idea what the un-
derlying mechanism of this disease is, and I realize that it might well
be that the spectrum from Barlow to fibroelastic deficiency is one
disease. The point of the paper is that once we recognize the nondu-
rable techniques, we still find that there is a progression of the dis-
ease. There is almost no difference anymore between the global sick
valve and the localized sick valve. If you call it Barlow or fibroelas-
tic deficiency, it does not matter.
Dr Galloway. That was my point. However, the question is,
even in the ‘‘optimal technique’’ group you have almost a 3% per
year failure rate in Barlow type valves. That is 30% over 10 years
in which you are going to have reoperation or 3 or 4+ mitral regur-
gitation.Would you advocate that we intervene prophylactically and
do chordal replacement on those patients now or not, or do you just
accept that late recurrence rate?
Dr Flameng. At the moment, I think we have to accept it, be-
cause there is no technique that can improve it above this or get
rid of this 2% or 3%.
Dr Galloway. That was the conclusion of the panel in the valve
repair postgraduate course. The recommendation was to leave a bil-
lowing but nonprolapsing anterior leaflet alone and repair only the
prolapsing posterior leaflet disease and put in an annuloplasty. It
is just an interesting point for consideration based on your data.
Second, you reported that flexible rings had a higher failure rate.
We have always bought into that idea, agreeing with Dr Carpentier
early on in the concept of more rigid geometric remodeling of the
annulus to make the repaired valve more convex to take tension
off, lower the strain, and therefore lessen the late failure rate. How-
ever, there are a lot of people who do not think that way and there are
a lot of people who believe that flexible devices are appropriate in
patients with degenerative disease. Do you have any data from
your echocardiography as to how valves with flexible devices failed
or why you think your failure rate was higher in that group?
Dr Flameng.We do not have any evidence that a flexible ring is
really inferior to a rigid ring. Not that many patients of our popula-
tion have a flexible ring, and when they do, there are different kinds
of flexible rings. Therefore, it is very difficult to say.
Dr Galloway. One last brief question. You showed in patients
with fibroelastic deficiency that lack of use of sliding plasty was as-
sociated with a higher failure rate. I think most people would use theThe Journal of Thosliding plasty technique mostly in patients who have a big height to
their posterior leaflet, more the Barlow type patients, trying to lower
the height of the posterior leaflet repair after repair. What techniques
did you use in patients with fibroelastic deficiency when you did not
do sliding plasty, and which of these techniques had the highest fail-
ure rate so we can stay away from them?
Dr Flameng. The point is that the sliding leaflet technique as de-
scribed by Professor Carpentier includes reduction of the posterior
leaflet by two additional triangular resections, and then you make
the posterior leaflet short. In fibroelastic deficiency, there is no
need for that. What we do then is just cut the posterior leaflet loose
and diminish the size of the ring by the mattress sutures put from the
left atrium to the ventricle. Then we replace the posterior leaflet. It is
more an annuloplasty than a leaflet plasty.
Dr Galloway. I understand what you did, but what about the
ones that failed? You said that patients who did not get a sliding
plasty had a higher failure rate. What techniques did you use in those
patients?
Dr Flameng. Many of these patients had no ring annuloplasty
because the ring dilatation is not so pronounced in fibroelastic defi-
ciency; you have patients with normal rings or with only mild dila-
tation of the ring. They either received no ring or no sliding
annuloplasty, which induced a higher failure rate.
Dr Galloway. A higher failure rate.
Dr Alain F. Carpentier (Paris, France). Dr Flameng, I enjoyed
your presentation very much. I remember very well when you pub-
lished your paper in Circulation. I was struck by your incidence of
recurrence, which was much higher than the one we had. Now today
you give us at least a part of the answer. Obviously, increasing ex-
perience and careful analysis of the risk factors involved may help to
identify this explanation.
You introduce an interesting distinction between an unfavorable
and a favorable operation. However, there are several factors in-
volved, patient-related or surgeon-related or technique-related, and
it is not easy to identify or to differentiate these different factors.
If we take the patient-related factor first, I notice that you had a rather
small incidence of Barlow compared with fibroelastic deficiency. In
our experience, it is about 50:50. Does it mean that many patients
with Barlow disease in your experience are operated on by valve re-
placement or does it mean that it was difficult for you to identify the
two groups?
Dr Flameng. It is well taken, because the overall rate of repair in
our population of patients having degenerative mitral disease was
nearly 80%, to be exact, 77%. But it changed over the years. In
the late 1980s the rate of repair was much lower than it is now.
Now it is almost 100%. At the beginning, it was mainly the Barlow
valves that were replaced instead of repaired, and that is why the
total number of Barlow valves in the series is lower, as in your
series, for example.
Dr Carpentier. Another question I have relates to the manage-
ment of the P2 prolapse in fibroelastic deficiency. In most instances,
we did not find it necessary to use a sliding plasty, so how do you
explain that? This may also relate to the difficulty in differentiating
the two groups.
Dr Flameng. It is really difficult to differentiate between the
groups, because there is always a gray zone in between. When
you have the clear fibroelastic deficiency as you described it, then
the number would be lower. Some patients we classified as havingracic and Cardiovascular Surgery c Volume 135, Number 2 281
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and consequently we performed more resections and sliding plas-
ties.
Dr Carpentier. I congratulate you for having made the effort to
make the distinction between Barlow and fibroelastic deficiency.
This is important not so much to predict the outcome but to predict
the feasibility and complexity of the repair, which is very important
information for the patient.
Dr Flameng. Thank you for your comment.
Dr David H. Adams (New York, NY). Professor, I would like to
congratulate you for your seminal work in teaching us the difference
between freedom from reoperation and freedom from recurrent
regurgitation, and teaching us to think more about recurrence of
mitral regurgitation. I think you and Tirone David deserve a lot of
credit for looking at your data that way.
I do not think this paper is going to give us the answer that we
all seek, which is the true difference between fibroelastic deficiency282 The Journal of Thoracic and Cardiovascular Surgery c Feand Barlow disease. I would submit to you, and I would like your
response, that there is a gray zone, and you have classified every
patient, which makes your data, in my mind, hard to interpret.
Why not take large ring sizes, for example, where there is less
argument. Take your size 36, 38, and 40 ring groups, and we will
be more comfortable calling that Barlow disease. Take your size
28, 30, and 32 ring groups with single segment prolapse, and we
will be more comfortable calling that fibroelastic deficiency. Do
a comparison of those two groups, and then I think we can get the
answer. What do you think? I think your gray zone is complicating
the interpretation of this information.
Dr Flameng. I do not have a clear answer for that. The only thing
I can say is that we followed Professor Carpentier’s identification of
the disease. And Professor Carpentier is working in Paris. Paris is
the capital of France, which is the biggest country in Europe.
Belgium’s capital is Brussels, and Belgium is the smallest country
in Europe. When it rains in Paris, it drops in Brussels. [Laughter].bruary 2008
